DEAR DR. ROACH: I was in excellent health until December 2020, when I was admitted to the hospital with high-risk multiple myeloma (MM). I’ve been participating in a Phase 2 clinical trial since January 2021, and I was fortunate to achieve minimal residual disease (MRD)-negative status in November 2023 -- a milestone that is reached by only 10% of over 20 participants. ...read more read less